suggested remit: To appraise the clinical and cost effectiveness of ripretinib within its marketing authorisation for advanced gastrointestinal stromal tumours (GIST) who have received previous treatment with tyrosine kinase inhibitors (TKI).
Status In progress
Process TAG
ID number 3805

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
07 January 2021 - 04 February 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
17 October 2018 In progress. DHSC referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance